

In re Findlay
Serial No.: to be assigned
Filed: concurrently herewith
Page 4

REMARKS

Claims 1-25 are pending in the above application. These claims are presented on Amended sheets 1-3 in the PCT International Preliminary Examination Report submitted herewith. Claims 4-6, 8-10, 13-16, and 18-19 have been amended to better conform to U.S. practice. Applicants respectfully request substantive examination on the merits.

Respectfully submitted,



Robert J. Smith
Attorney for Applicants
Registration No. 40,820



20792


PATENT TRADEMARK OFFICE

CERTIFICATE OF EXPRESS MAILING

"Express Mail" mailing label number EL920740840US

Date of Deposit: August 13, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Box Patent Application, Assistant Commissioner for Patents, Washington, DC 20231.



Keowanna V.C. Best
Date : August 13, 2001

2007-08-13 10:00

Version With Markings To Show Changes Made

4. (Amended) Use of **[any claims 1 to 3]** claim 1 wherein said binding domain and/or said targeting domain is endogenous to the calycin or calycin multimer.

5. (Amended) Use of **[any claims 1 to 3]** claim 1 wherein said binding domain and/or said targeting domain is adapted by alteration of the endogenous binding and/or targeting domain or by substitution of the endogenous binding and/or targeting domain for a domain that has the required functionality.

6. (Amended) Use of **[any claims 1 to 5]** claim 1 wherein said binding domain is adapted to bind more than one ligand.

8. (Amended) Use of **[any claims 1 to 7]** claim 1 wherein the **[or]** at least one calycin has the ability to bind fatty acids that coat hair cuticles and/or skin or protein moieties that comprise the cuticle and/or skin.

9. (Amended) Use of claim 1 **[any of the preceding claims]** wherein the **[or]** at least one calycin is β -lactoglobulin.

10. (Amended) Use of **[any claims 1 to 8]** claim 1 wherein the **[or]** at least one calycin is Major Urinary Protein and/or recombinant Major Urinary Protein.

13. (Amended) A method according to **[claim 11 and/or claim 12]**claim 11 wherein the calycin comprises a molecular complex with more than one type of ligand binding domain, wherein calycin genes are fused to one another and/or appropriate linking regions are used to produce a multi component gene and gene product and/or interaction sites are introduced into individual monomers of the calycins such that on mixing the individual proteins, molecules assemble into multi-sub unit complexes with similar or different functionalities.

0913622-10801

14. (Amended) A method according to **[claim 11 and/or claim 12]**claim 11 wherein said method comprises chemical methods in the crosslinking of calycin monomers to form multimeric complexes.

15. (Amended) A method of claim 13 further comprising chemical methods in the crosslinking of calycin monomers to form multimeric complexes **[a method of claim 14]**.

16. (Amended) A method of **[claim 14 or 15]** claim 14 wherein said chemical methods include the use of a bifunctional cross-linking agent.

18. (Amended) A method of **[claims 11 to 17]** claim 11 to effect the cross-linking of β - Lactoglobulin and recombinant Major Urinary Protein.

19. (Amended) Use of hair or skin care composition at least one calycin as defined in **[claims 1 to 10]** claim 1.

0913522-10801
"ASSET 660"